Clinical trials: T-Cell Lymphocytic Leukemia
Leukemia
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.
- Trial name
- NCT00005802
- Testing
- aldesleukin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Lymphocytic Leukemia, Graft vs Host Disease
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
Cancers of the blood, sometimes referred to as hematologic malignancies, are disorders of bone marrow cells that lead to the failure of the normal function of bone marrow and the uncontrolled growth of cancerous cells in the bone…
- Conditions
- Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma
- Trial name
- NCT00001873
- Testing
- Isolex 300i plus MoAbs
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT03467256
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Fludarabine, Cyclophosphamide
- Where
- Russia
- Volunteers
- 18 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with untreated acute lymphoblastic leukemia.
- Conditions
- Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, L1 Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00061945
- Testing
- allopurinol, cyclophosphamide, daunorubicin hydrochloride
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced solid…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00025129
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
This phase I/II trial tests the safety and how well intravenous interferon-beta-1a (FP-1201) works in preventing toxicities after CD19-directed chimeric antigen receptor (CAR) T-cell therapy in patients with B-cell cancers that…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT05936229
- Testing
- Interferon Beta-1A, X-Ray Imaging, Echocardiography
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
This phase I trial tests the safety and side effects of B-cell activating factor receptor (BAFFR) chimeric antigen receptor (CAR) T cells and how well they work in treating patients with B-cell acute lymphoblastic leukemia…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
- Trial name
- NCT07758673
- Testing
- Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
B-cell Non Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Treatment of Hematological Malignancy With Novel CAR-T Cells.
This is a single arm, open-label, early phase I study, to determine the safety and efficacy of Novel CAR-T cell therapy in Hematological Malignancy treatment.
- Conditions
- B-cell Non Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma
- Trial name
- NCT04191941
- Testing
- Novel CAR-T
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Timmune Biotech Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
This phase I trial is studying the side effects and best dose of 7-hydroxystaurosporine when given together with perifosine in treating patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia, or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00301938
- Testing
- 7-hydroxystaurosporine, perifosine, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Small Intestine Cancer
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00562068
- Testing
- alemtuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 5 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Leukemia/Lymphoma, Cutaneous T Cell Lymphoma
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until…
- Conditions
- Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
- Trial name
- NCT04014374
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Kyowa Kirin, Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01789255
- Testing
- vorinostat, tacrolimus, cyclosporine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin in treating young patients with relapsed…
- Trial name
- NCT00085150
- Testing
- LMB-2 immunotoxin
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
MS-275 in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have hematologic cancer.
- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00015925
- Testing
- entinostat
- Where
- 2 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
B-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
This study evaluates the value of bortezomib in combination with specified chemotherapies for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL), Recurrent Adult Acute Lymphoblastic Leukemia (ALL), T-cell Adult Acute Lymphoblastic Leukemia (ALL)
- Trial name
- NCT01769209
- Testing
- Bortezomib, Doxorubicin hydrochloride (HCl), PEG-Asparaginase
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia
Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia
This is an open-label, single-institution pilot study of single-agent golidocitinib enrolling up to 24 patients in two cohorts: a) advanced-stage mycosis fungoides/Sézary syndrome (MF/SS), n=12, or b) T-cell large granular…
- Trial name
- GEMSTONE (NCT07682792)
- Testing
- Golidocitinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Acute Leukemia, Acute Lymphoblastic Leukemia
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission.
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT03970096
- Testing
- Total-Body Irradiation, Thiotepa, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia, Leukemia
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
The addition of ponatinib to mini-hyper-CVD chemotherapy and venetoclax will improve the complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia
- Trial name
- NCT05268003
- Testing
- Ponatinib, Venetoclax, Mini-hyper CVD
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Leukemia
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Primary objective: To determine the safety of adback T- or Natural Killer (NK) cells in patients with lymphoid malignancies receiving allogeneic stem cell transplantation with Campath-IH containing conditioning regimen.
- Trial name
- NCT00536978
- Testing
- ARA-C, BCNU, Campath-1H
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.